...
首页> 外文期刊>Journal of Clinical Microbiology >Multicenter Clinical Validation of the Molecular BD Max Enteric Viral Panel for Detection of Enteric Pathogens
【24h】

Multicenter Clinical Validation of the Molecular BD Max Enteric Viral Panel for Detection of Enteric Pathogens

机译:BD最大肠病毒分子检测肠病原菌的多中心临床验证

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The conventional methodology for gastrointestinal pathogen detection remains time-consuming, expensive, and of limited sensitivity. The objective of this study was to evaluate the performance of the BD Max enteric viral panel (Max EVP) assay for identification of viral pathogens in stool specimens from individuals with symptoms of acute gastroenteritis, enteritis, or colitis. ABSTRACT The conventional methodology for gastrointestinal pathogen detection remains time-consuming, expensive, and of limited sensitivity. The objective of this study was to evaluate the performance of the BD Max enteric viral panel (Max EVP) assay for identification of viral pathogens in stool specimens from individuals with symptoms of acute gastroenteritis, enteritis, or colitis. Prospective and archival stool specimens from adult and pediatric patients with diarrhea were collected in Cary-Blair medium or unpreserved containers. The results for specimens tested by the Max EVP (on the BD Max platform) were compared to those obtained by the reference method (alternate PCR assays, followed by bidirectional sequencing). Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated. A total of 2,239 specimens were collected, with 2,148 being included for analysis. In this population, 39.6% of specimens were from outpatients, 42.1% were from patients &21?years old, and 49.7% were from females. Prevalence rates for prospective specimens were 7.3%, 4.5%, 3.5%, 2.4%, and 1.2% for norovirus, sapovirus, astrovirus, rotavirus, and adenovirus, respectively. PPA was 92.8%, 84.9%, 93.0%, 100%, and 95.6%, for norovirus, sapovirus, astrovirus, rotavirus, and adenovirus, respectively. NPA was ≥99.4% for all targets. In conjunction with the clinical presentation, laboratory findings, and epidemiological information, the Max EVP assay is effective for the differential diagnosis of enteric disease caused by norovirus, sapovirus, astrovirus, rotavirus, and adenovirus. This assay can be used individually for patients at high risk for a viral enteropathogen (e.g., in outbreak settings) or as an adjunct to other enteric bacterial panels.
机译:胃肠道病原体检测的常规方法仍然耗时,昂贵且灵敏度有限。这项研究的目的是评估BD Max肠道病毒平板(Max EVP)测定法在鉴定患有急性肠胃炎,肠炎或结肠炎症状的人的粪便标本中的病毒病原体的性能。摘要胃肠道病原体检测的常规方法仍然耗时,昂贵且灵敏度有限。这项研究的目的是评估BD Max肠道病毒平板(Max EVP)测定法在鉴定患有急性肠胃炎,肠炎或结肠炎症状的人的粪便标本中的病毒病原体的性能。将成年和小儿腹泻患者的前瞻性和档案性粪便标本收集在Cary-Blair培养基或未保存的容器中。将通过Max EVP(在BD Max平台上)测试的样品的结果与通过参考方法(备用PCR分析,然后进行双向测序)获得的结果进行比较。计算出正百分比同意率(PPA)和负百分比同意率(NPA)。总共收集了2239个样本,其中2148个样本用于分析。在该人群中,39.6%的样本来自门诊病人,42.1%的样本来自21岁以下的病人,49.7%的样本来自女性。诺如病毒,沙波病毒,星状病毒,轮状病毒和腺病毒的预期标本患病率分别为7.3%,4.5%,3.5%,2.4%和1.2%。诺如病毒,沙波病毒,星状病毒,轮状病毒和腺病毒的PPA分别为92.8%,84.9%,93.0%,100%和95.6%。所有目标的NPA≥99.4%。结合临床表现,实验室检查结果和流行病学信息,Max EVP检测可有效鉴别由诺如病毒,沙波病毒,星形病毒,轮状病毒和腺病毒引起的肠道疾病。该测定法可单独用于病毒性肠病原高风险患者(例如在暴发环境中)或作为其他肠细菌菌群的辅助药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号